Novo Nordisk generates the majority of its revenue from its GLP-1 franchise. The company's semaglutide, marketed under brands such as Wegovy for weight loss and Ozempic for diabetes, has been a market ...

Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce. Novo Nordisk’s U.S.-listed shares ...

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which chips in on the blockbuster GLP-1 medications Ozempic and Wegovy. All told, ...

Novo Nordisk A/S’s Chairman Lars Rebien Sorensen faced intense scrutiny from investors at the company’s annual general meeting on Thursday, the first after his boardroom coup last year. Sorensen and ...

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that ...

Just when you think Novo Nordisk A/S (NVO) can't go any lower, it gets some more bad news, and the stock dips further. The stock already collapsed in 2025 as GLP-1 enthusiasm faded and political ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Viewed from another perspective, though, it doesn't cost much more than it did back when the Ozempic craze began five years ago. Investors today have been given a second chance to buy, hold, and ...

Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...